Hwangryunhaedok-Tang (HR) and berberine-containing single herbs are used to treat bacterial infection and inflammatory\r\ndiseases in eastern Asia. The combination of berberine-containing herbal medicines and ciprofloxacin can be an excellent\r\nantibacterial chemotherapy against multidrug resistance bacteria. To evaluate the pretreatment effect of berberine and HR,\r\nvehicle, berberine (25 and 50 mg/kg/day), and HR (1.4 g/kg/day) were daily administered to rats for five consecutive days. On\r\nday 6, ciprofloxacin was administered (10 mg/kg, i.v. and 20 mg/kg, p.o.) to rats. To assess cotreatment effect of berberine and\r\nciprofloxacin, berberine (50 mg/kg) and ciprofloxacin (20 mg/kg) were coadministered by single oral gavage. Pharmacokinetic data\r\nwere estimated by noncompartmental model. Compared with ciprofloxacin alone (control group), coadministration of berberine\r\n(50 mg/kg) and ciprofloxacin significantly decreased Cmax of ciprofloxacin (P < 0.05). In addition, the pretreatment of berberine\r\n(50 mg/kg/day) and HR (1.4 g/kg/day) significantly decreased Cmax and AUC0?8, compared with control group (P < 0.05). The\r\noral bioavailability of ciprofloxacin was reduced by cotreatment of berberine and pretreatment of berberine and HR. Our results\r\nsuggest that the expression of P-glycoprotein and organic anion and/or organic cation transporters (OAT/OCT) could take a role\r\nin reduced oral bioavailability of ciprofloxacin by berberine and HR.
Loading....